Ribon Therapeutics and Pfizer have entered into an agreement to leverage Pfizer's global development expertise and capabilities to support the advancement of Ribon's pipeline. Ribon will retain economic rights and control of clinical development across all its programs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.81 USD | +0.40% | +9.49% | -3.40% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.40% | 157B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
+8.08% | 149B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Ribon Therapeutics and Pfizer Have Enter into an Agreement